As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...
AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan ...
Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...
It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback